^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB86550

    i
    Other names: INCB86550, INCB-86550, INCB-086550, INCB 086550, INCB086550
    Company:
    Incyte
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    12d
    Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects. (PubMed, ChemMedChem)
    Early clinical trials of CA-170, INCB086550, and ASC61 indicate encouraging activity in solid tumors, including CRC. This review summarizes the role of the PD-1/PD-L1 axis in CRC and discusses the therapeutic potential and future prospects of small-molecule inhibitors as next-generation immunotherapies for CRC.
    Review • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • B2M (Beta-2-microglobulin)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    11ms
    Dual inhibition of JAK3 and PD-L1 boosts immune response in triple negative breast cancer. (PubMed, Anticancer Drugs)
    We verified the efficacy of the combination of the selective TYK2 inhibitor Deucravacitinib and the small molecule inhibitor of PD-L1, INCB086550, in two TNBC animal models: a syngeneic mouse model (4T1 with humanized PD-L1) and a peripheral blood mononuclear cell (PBMC)-humanized model (MDA-MB-231). This enhanced antitumor effect is associated with the modulation of antitumor immune-related gene expression by the combined therapy. The combination of TYK2 inhibitors and immune checkpoint inhibitors is a potentially effective strategy for treating TNBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TYK2 (Tyrosine Kinase 2)
    |
    INCB86550
    12ms
    To assess the safety, tolerability and pharmacokinetics of INCB86550 in healthy adult population. (ACTRN12621000103864)
    P1, N=75, Completed, Incyte Corporation | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • INCB86550
    over1year
    Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
    P2, N=16, Terminated, Incyte Corporation | Trial completion date: Aug 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
    Trial completion date • Trial termination • Checkpoint inhibition
    |
    INCB86550
    2years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    INCB86550
    over2years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, Incyte Corporation | Trial completion date: Sep 2023 --> Feb 2024
    Trial completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over2years
    Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Incyte Corporation | N=150 --> 16 | Trial completion date: May 2023 --> Aug 2024 | Trial primary completion date: May 2023 --> Mar 2024
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    INCB86550
    over2years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, Incyte Corporation | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    almost4years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=128, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over4years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=128, Recruiting, Incyte Corporation | N=372 --> 128
    Clinical • Enrollment change
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over4years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=372, Recruiting, Incyte Corporation | N=230 --> 372 | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    almost5years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=230, Recruiting, Incyte Corporation | N=128 --> 230 | Trial completion date: Aug 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Sep 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550